Sponsors

At AbbVie, we have the expertise of a proven pharmaceutical leader and the focus and passion of an entrepreneur and innovator. The result is something rare in health care today – a global biopharmaceutical company that has the ability to discover and advance innovative therapies and meet the health needs of people and societies around the globe.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need.

Boehringer Ingelheim is a global pharmaceutical company focused on innovative treatments for diseases with high unmet medical need. Privately owned since 1885, the company combines scientific excellence with a long-term commitment to improving patient health.

Dr. Falk Pharma GmbH is an independent family firm based in Freiburg im Breisgau. In spite of its international presence, Dr. Falk Pharma and its 200 staff are still closely linked with the Freiburg region and the University of Freiburg. Our company specializes in the development and sales of medication for indications in hepatology and gastroenterology. These, mainly prescription drugs, are sold not only in Germany but also in a further 65 countries, often in co-operation with local partners but in some cases also via our own subsidiary companies.

In Latin, “mirum” means remarkable, wondrous, or extraordinary. Here at Mirum, we see beyond rare diseases—we see the people. With creativity and heart, we light the way for those searching for hope. Because every breakthrough we make is not just medicine—it’s a moment of joy, a chance for patients to live fully. What we do at Mirum is nothing short of “raremarkable.” That’s why our name is so fitting.

At echosens, we envision a future where medical professionals and their patients have the best tools and information to assess and manage liver health.

We are a global, mid-size pharmaceutical company focusing on areas of high unmet medical need.
With a focus on transformative medicines in oncology, rare disease and neuroscience, our vision is to be a leading global mid-size biopharmaceutical company. With the right combination of size and agility, we continue to push ourselves as a business and as individuals to deliver positive change.

Novo Nordisk’s purpose is to drive change to defeat serious chronic diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.